Development of a Novel targeted nanoparticle drug delivery system for breast cancer medication Colleen Clark, Villanova University
In recent years, a major challenge of the pharmaceutical community has been to develop an effective and noninvasive way to treat and target tumors. This project proposes the use of a drug encapsulated within a microparticle comprised of a polymer shell—poly (D, L lactic-co-glycolide acid) (PLGA). A cancer drug will be encapsulated within the polymer shell and the shell will be coated with a covalently linked targeting mechanism for attaching the particles to cancerous cells. The targeting method used was a biotin-avidin linkage as well as a targeting antibody. Using a polymer shell allows for the slow release of the drug over time as it naturally degrades in the body. The linkage will allow for the drug to be released in areas only containing cancerous cells, leaving healthy cells alone. The focus of this study is to characterize the size, morphology, encapsulation, and release efficiency of the particles using, at first, a model drug, and then a cancer drug. Microparticles were synthesized using a double emulsion process with 5 wt% PVA as the surfactant and ethyl alcohol as the oil phase. Particles were made using the model drug, Bovine Serum Albumin (BSA), for encapsulation efficiency and release testing, both analyzed through the use of a micro BCA protein assay. In additional studies, the BSA was replaced with Taxol, which is a mitotic inhibitor. The protocol was altered slightly using the same double emulsion process. PVA was used as the surfactant and dichloromethane was used as the oil phase. Release and encapsulation studies were performed in vitro in both cases.